Laboratorio Reig Jofre, S.A. acquired remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E.
July 22, 2021
Share
Laboratorio Reig Jofre, S.A. (BME:RJF) acquired remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E. on July 22, 2021.
Laboratorio Reig Jofre, S.A. (BME:RJF) completed the acquisition of remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E. on July 22, 2021.
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Companyâs activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Laboratorio Reig Jofre, S.A. acquired remaining 49% stake in Reig Jofre UK Ltd from FIEX managed by Compañía Española de Financiación del Desarrollo, COFIDES, S.A, S.M.E.
LABORATORIO REIG JOFRE, S.A. 